Protocol Ledger

NCT05848765 · Phase II · RECRUITING

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Interventional Phase II clinical trial protocol NCT05848765 sponsored by University of Birmingham in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-09-04 Enrollment: 284 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05848765
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)284 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05848765
Protocol FieldVerified Registry Value
NCT IdentifierNCT05848765
Consolidated Lead SponsorUniversity of Birmingham
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment284 participants (ESTIMATED)
Registered Start Date2023-09-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05848765
Hospital Research SiteLocationSite Profile
University Hospitals Birmingham NHS Foundation TrustBirmingham, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI